TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06343337

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation of DMFT index, CPI scores, salivary pH and flow rate in pregnant and non-pregnant woman
Description: Total 198 volunteer (51 women for control, 47 women for 1st trimester, 51 women for 2nd trimester, and 49 women for 3rd trimester) were included. The data about sociodemographic characteristics, dental and systemic health conditions were recorded. Unsitumulated saliva samples were collected for 5 minutes by spitting method. The pH of saliva was measured by a portable pHmeter. The salivary flow rate was determined by the weight measurement method. DMFT index and CPI scores were determined. The statistical differences were evaluated by Kruskal-Wallis, Mann Whitney U and Chi Square tests (α=.05).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Evaluation of DMFT index, CPI scores, salivary pH and flow rate in pregnant and non-pregnant woman
Description: Total 198 volunteer (51 women for control, 47 women for 1st trimester, 51 women for 2nd trimester, and 49 women for 3rd trimester) were included. The data about sociodemographic characteristics, dental and systemic health conditions were recorded. Unsitumulated saliva samples were collected for 5 minutes by spitting method. The pH of saliva was measured by a portable pHmeter. The salivary flow rate was determined by the weight measurement method. DMFT index and CPI scores were determined. The statistical differences were evaluated by Kruskal-Wallis, Mann Whitney U and Chi Square tests (α=.05).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation of DMFT index, CPI scores, salivary pH and flow rate in pregnant and non-pregnant woman
Description: Total 198 volunteer (51 women for control, 47 women for 1st trimester, 51 women for 2nd trimester, and 49 women for 3rd trimester) were included. The data about sociodemographic characteristics, dental and systemic health conditions were recorded. Unsitumulated saliva samples were collected for 5 minutes by spitting method. The pH of saliva was measured by a portable pHmeter. The salivary flow rate was determined by the weight measurement method. DMFT index and CPI scores were determined. The statistical differences were evaluated by Kruskal-Wallis, Mann Whitney U and Chi Square tests (α=.05).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation of DMFT index, CPI scores, salivary pH and flow rate in pregnant and non-pregnant woman
Description: Total 198 volunteer (51 women for control, 47 women for 1st trimester, 51 women for 2nd trimester, and 49 women for 3rd trimester) were included. The data about sociodemographic characteristics, dental and systemic health conditions were recorded. Unsitumulated saliva samples were collected for 5 minutes by spitting method. The pH of saliva was measured by a portable pHmeter. The salivary flow rate was determined by the weight measurement method. DMFT index and CPI scores were determined. The statistical differences were evaluated by Kruskal-Wallis, Mann Whitney U and Chi Square tests (α=.05).
Study: NCT06410846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TopSpin360
Description: Neck strength and conditioning device used during neck strengthening program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck Strengthening Exercise Plan
Description: Physical therapist designed neck strengthening program.
Study: NCT04958161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Each exercise session will involve 5 to10 minutes of stretching and slow walking followed by a 30 minute stimulus phase of aerobic exercise. Exercise intensity during the stimulus phase will be prescribed based on the graded exercise test results and will be gradually increased with the goal of the participant exercising continuously for 30 minutes at 50% to 85% of symptom-limited maximum heart rate, or maintained at a level below that which causes symptomatic or silent ischemia. Following the aerobic phase of exercise, participants will complete one set of 8 to 12 repetitions of muscle-strengthening activities for all major muscle groups (legs, hips, back, abdomen, chest, shoulders, and arms). Participants will be provided with a home based aerobic exercise program. They will be encouraged to perform this home-based program twice a week on days when they are not attending the center-based program.
Study: NCT04723407

Intervention type: OTHER
Intervention: questionnaires
Description: Questionnaire completion

Intervention type: OTHER
Intervention: questionnaires
Description: Questionnaire completion
Study: NCT06245798

Intervention type: PROCEDURE
Intervention: transarterial chemoembolisation
Description: During transarterial chemoembolisation（TACE）, a vascular catheter was selectively inserted into the tumour-feeding artery with an injection containing a mixture of doxorubicin (10-50 mg) and lipiodol (2-20 mL), followed by embolisation using gelatin sponge particles. TACE was repeated when residual viable tumours were confirmed or new lesions developed in patients with adequate liver function
Study: NCT04725890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The DyaMX Device
Description: The DyaMX device is designed to induce duodenal mucosal regeneration using pulsed electric field. The DyaMX procedure is a non-surgical, endoscopic procedure.
Study: NCT06212570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KeySuite
Description: KeyScope and KeyLoop will be used to perform biopsies of intra-abdominal masses and cancers.
Study: NCT05513768

Intervention type: DIAGNOSTIC_TEST
Intervention: level of myosin binding protein c in serum
Description: Serum samples will be taken from the participants in the first trimester, transferred to eppendorf tubes after appropriate procedures, and stored at -80 degrees until the time of deliveryParticipants will be divided into two groups according to the timing of birthThe first group is those who gave birth earlier than 37 weeks those who gave birth on time in the other group The mbpc levels will be looked at and compared.

Intervention type: DIAGNOSTIC_TEST
Intervention: level of myosin binding protein c in serum
Description: Serum samples will be taken from the participants in the first trimester, transferred to eppendorf tubes after appropriate procedures, and stored at -80 degrees until the time of deliveryParticipants will be divided into two groups according to the timing of birthThe first group is those who gave birth earlier than 37 weeks those who gave birth on time in the other group The mbpc levels will be looked at and compared.
Study: NCT05450406

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: The participants will receive the possibility to attend weekly endurance, resistance and yoga exercise sessions administered by the Healthy Life Center. They will also receive personalized follow-up from the Healthy Life Center, and have the possibility to exercise at the local gym.
Study: NCT05032846

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Ovarian Cystectomy
Description: Laparoscopic Ovarian Cystectomy will be performed as standard clinical practice.
Study: NCT06612918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-intensity laser acupuncture and the exercise program
Description: The experimental group will receive high-intensity lasers, and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40, and GB30. Exercises program: The patients will perform this exercise program in the form of: strengthening exercises for abdominal and back muscles; lumbar stabilization exercises; and stretching exercises.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham laser acupuncture and the exercises program
Description: The patients will receive a sham laser acupuncture and the exercise program in the form of: strengthening exercises for abdominal and back muscles; lumbar stabilization exercises and stretching exercises.
Study: NCT06730932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS004（BTLA monoclonal antibody，intravenously）,Toripalimab（ anti-PD-1specific antibody，intravenously)
Description: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection 200mg via IV infusion once every 3 weeks~Toripalimab 240mg via IV infusion once every 3 weeks~JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
Study: NCT05695820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction training
Description: It is a method that involves reducing blood flow to a muscle by the application of an external constricting device, such as a blood pressure cuff or tourniquet, to provide mechanical compression of the underlying blood vessels. BFR is applied aiming to enhance blood pooling in the capillary beds of the limb muscles distal to the tourniquet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction training
Description: It is a method that involves reducing blood flow to a muscle by the application of an external constricting device, such as a blood pressure cuff or tourniquet, to provide mechanical compression of the underlying blood vessels. BFR is applied aiming to enhance blood pooling in the capillary beds of the limb muscles distal to the tourniquet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction training
Description: It is a method that involves reducing blood flow to a muscle by the application of an external constricting device, such as a blood pressure cuff or tourniquet, to provide mechanical compression of the underlying blood vessels. BFR is applied aiming to enhance blood pooling in the capillary beds of the limb muscles distal to the tourniquet
Study: NCT05233579

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning. The supplement should be taken around the same time each day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning. The supplement should be taken around the same time each day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning. The supplement should be taken around the same time each day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning. The supplement should be taken around the same time each day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning. The supplement should be taken around the same time each day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning. The supplement should be taken around the same time each day.
Study: NCT04923945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Patients meeting the study inclusion criteria will receive Savolitinib \[Savolitinib 600 mg, po, once per day (QD) continuously in patients with baseline weight ≥50 kg, and Savolitinib 400 mg, po, QD in patients with baseline weight \<50 kg\] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest.
Study: NCT05009199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-444
Description: Subjects will undergo PET imaging using \[18F\]MNI-444.
Study: NCT04745845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noradrenalin
Description: Norepinephrine challenge (concentration 'A' ) in fluid responsive position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noradrenalin
Description: Norepinephrine challenge (concentration 'A') in non-fluid responsive position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noradrenalin
Description: Norepinephrine challenge (concentration 'B') in fluid responsive position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noradrenalin
Description: Norepinephrine challenge (concentration 'B') in non-fluid responsive position
Study: NCT05473936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker led curriculum
Description: The intervention arm will consist of a CHW-based health educational program via Zoom, where participants will be provided with information about COVID-19, COVID-19 resources and services in Los Angeles County, and engagement with Los Angeles County Department of Health Services CHWs who will lead the curriculum and be available to answer questions of the intervention arm patients.
Study: NCT05421767

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nerve stimulation guided renal denervation procedure
Description: RNS-in

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve stimulation guided renal denervation procedure
Description: RNS-in

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nerve stimulation guided renal denervation procedure
Description: RNS-in
Study: NCT06131775

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: One blood sample of 10mL is realized before initiation of immunotherapy

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: Three blood samples of 10mL are realized at distinct steps of patients disease management : one before the curative surgery, one after three months and one after six months.
Study: NCT06055803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intake Session
Description: Each of the program components will have an individualized assessment with plan and goals set at the program intake visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Sessions
Description: Individual sessions will occur in person or virtual every other week during the 12-week intervention with a health promotion specialist (nurse or exercise physiologist). These sessions will include review of progress towards goals, update exercise prescription, make plan for the next two weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Sessions
Description: Group sessions for wellness and education will be delivered by medical multi-disciplinary staff in person or virtual every other week during the 12-week intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graduation
Description: At the conclusion of the 12-week intervention, there will be a graduation session to honor the participant's achievement and establish a plan for maintenance after the intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will exercise as part of individual and group sessions. Participants will also be asked to exercise on their own, with a goal of working up to meeting US Physical Activity guidelines (150 minutes per week of moderate to vigorous exercise + 2 episodes of strength training).
Study: NCT05196880

Intervention type: DEVICE
Intervention: MolecuLight DX Imaging Device
Description: The MolecuLight DX Imaging Device is a fluorescence imaging device intended to acquire images from wounds. This will not alter the participant's standard of care treatment.
Study: NCT06079632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent coaching via telehealth
Description: Participants receive 12 weeks of parent-child interaction strategy coaching and sensory processing strategy coaching intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent coaching via telehealth
Description: Participants receive 12 weeks of parent-child interaction strategy coaching and sensory processing strategy coaching intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weekly self-learning materials and group discussion session
Description: Participants receive 1-hour self-learning materials, including parent-child interaction and sensory processing strategies, and 1-hour remote group discussion session weekly.
Study: NCT05061901

Intervention type: DRUG
Group type: OTHER
Intervention: Lisinopril tablet 20 mg
Description: Lisinopril is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 20 mg of lisinopril.

Intervention type: DRUG
Group type: OTHER
Intervention: Zestril® tablet 20 mg
Description: Zestril® is manufactured by Avara Reims Pharmaceutical Services, France. Each tablet contains 20 mg of lisinopril.
Study: NCT05299762

Intervention type: DEVICE
Intervention: INFUSE™ Bone Graft
Description: Ministry of Food and Drug Safety (MFDS) has approved the INFUSE™ Bone Graft for anterior (ALIF) or oblique (OLIF) lumbar interbody spine fusion as a substitute for autogenous bone graft for patients with degenerative disc disease (DDD) who have had at least 6 months of non-operative treatment for this condition.
Study: NCT05420493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Description: Drug: CAR-T cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study: NCT06356324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Intervention
Description: Participants assigned to 20 minutes of music listening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Television Intervention
Description: Participants assigned to 20 minutes of television viewing
Study: NCT05920863

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE: pharmorubicin 30mg, oxaliplatin 50mg, cycle 4-5 week.
Study: NCT04808414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPX9003 for IV Infusion
Description: antibiotic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for IV infusion
Description: Placebo comparator
Study: NCT05639686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: Within 10 minutes of general anesthetic induction, 15mg/kg TXA suspended in 100mL of normal saline will be administered intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Total Intravenous Anesthesia
Description: Within 10 minutes of induction, patients in the control (TIVA) group will be administered a 100mL bolus of normal saline as placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhalational isoflurane
Description: Inhalational isoflurane or sevoflurane will be administered as a general anesthetic at the induction of the surgical procedure.
Study: NCT06074627

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Energy Placebo Control Form 1
Description: Participants will use their Radicle Energy Placebo Control Form 1 as directed for a period of 6 weeks.
Study: NCT05920863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab, Lenvatinib
Description: Tislelizumab: 200mg, cycle 3 week. Lenvatinib: weight \<60kg, 8mg/day; weight ≥60kg, 12mg/day.
Study: NCT03219450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeoVax
Description: It stimulates the immune system to attack cancer cells.
Study: NCT05750589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX-101
Description: IRX-101 is a novel ocular anti-septic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Providone-Iodine
Description: 5% Providone-Iodine
Study: NCT03219450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeoVax
Description: It stimulates the immune system to attack cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeoVax
Description: It stimulates the immune system to attack cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: It is a chemotherapy drug used to treat many cancers. At low doses, it is an investigational drug to help the immune cells to be better at attacking cancer cells while avoiding chemotherapy toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: It is a chemotherapy drug used to treat many cancers. At low doses, it is an investigational drug to help the immune cells to be better at attacking cancer cells while avoiding chemotherapy toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Is a monoclonal antibody that helps the immune cells to be better at attacking cancer cells.
Study: NCT05401370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Methylene blue dye
Description: For MB group, the staining of the glandular tissue will be obtained with 3-4 mL of 1% MB that will be introduced into the gland via the salivary duct several minutes before the surgery.The trans-oral catheterization of the Stensen's duct will be performed and the solution will be injected via intravenous cannula.The glandular tissue will turn dark blue.
Study: NCT04983979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate
Description: sachets of 5g or 10g given OD titrated to serum potassium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo given titrated according to potassium at a dose to 5 or 10g
Study: NCT06316505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral hygiene motivation with individual oral photograps
Description: Oral photograps was taken at control sessions.
Study: NCT06074627

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Active Study Product 1.1 Usage
Description: Participants will use their Radicle Energy Active Study Product 1.1 as directed for a period of 6 weeks.
Study: NCT06110065

Intervention type: DRUG
Intervention: CT-guided Pudendal Nerve Cryoneurolysis
Description: CT-guided bilateral pudendal nerve cryoneurolysis involves using advanced imaging technology to precisely target and freeze the pudendal nerves, which are responsible for transmitting pain signals.

Intervention type: DRUG
Intervention: Percutaneous image-guided cryoneurolysis
Description: Percutaneous image-guided cryoneurolysis focuses on using extremely cold temperatures to alleviate pain originating from the pudendal nerves. This method has demonstrated extended pain relief compared to alternatives like injections or catheters. Additionally, it presents a lower risk of certain complications.